Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
Type:
Grant
Filed:
May 20, 2013
Date of Patent:
March 24, 2015
Assignee:
Novartis AG
Inventors:
Matthew Burger, Joseph E. Drumm, III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
Abstract: The invention relates to lipoic acid acylated salicylate derivatives; compositions comprising an effective amount of a lipoic acid acylated salicylate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a lipoic acid acylated salicylate derivative.
Type:
Grant
Filed:
October 5, 2010
Date of Patent:
February 3, 2015
Assignee:
Catabasis Pharmaceuticals, Inc.
Inventors:
Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
Abstract: The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions comprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat.
Type:
Grant
Filed:
June 24, 2011
Date of Patent:
February 3, 2015
Assignee:
Sandoz AG
Inventors:
Andreas Hotter, Ulrich Griesser, Verena Adamer, Christoph Langes
Abstract: The invention relates to compounds of the general formula (I), where R1 is a branched alkyl(ene) radical having from 10 to 22 carbon atoms and having at least one branch in position 1, 2, 3 or 4 relative to the oxygen atom, R2 is a linear or branched alkyl(ene) radical having from 1 to 13 carbon atoms and R1 and R2 are selected so that the total number of carbon atoms in formula (I) is from 11 to 23. The compounds of the invention are suitable for preparation of or in cosmetic and/or pharmaceutical preparations, in particular as oily substances.
Type:
Grant
Filed:
July 22, 2011
Date of Patent:
January 27, 2015
Assignee:
Cognis IP Management GmbH
Inventors:
Burkhard Beckedahl, Markus Dierker, Rolf Kawa, Stefan Brüning
Abstract: The present invention provides a combination comprising (a) a compound of formula (I) and (b) one or more antineoplastic agents selected from the group consisting of an antimetabolite agent, analkylating or alkylating-like agent, an intercalating agent, a topoisomerase I or II inhibitor, an antimitotic agent, a kinase inhibitor, a proteasome inhibitor and an antibody inhibiting a growth factor or its receptor, wherein active ingredients of the combination are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate or solvate thereof, useful in the treatment of tumors.
Type:
Grant
Filed:
May 21, 2010
Date of Patent:
January 6, 2015
Assignee:
Nerviano Medical Sciences S.R.L.
Inventors:
Barbara Valsasina, Italo Beria, Antonella Ciavolella, Dario Ballinari, Enrico Pesenti, Juergen Moll, Mara Emanuela Casnaghi, Alessandro Luciano Croci
Abstract: Ecteinascidin formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.
Type:
Grant
Filed:
October 28, 2005
Date of Patent:
November 25, 2014
Assignee:
Pharma Mar, S.A., Sociedad Unipersonal
Inventors:
Jacob Hendrik Beijnen, Bastiaan Nuijen, Pilar Calvo Salve, Maria Tobio Barreira
Abstract: The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
Abstract: The invention relates to fused-imidazoyl compounds of Formula (I): wherein ring A, R1, R2, R3, R4, R5, R6, R7, R8, R9, m and n are as defined herein. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and methods of using the compound of Formula (I) to treat microbial infections.
Abstract: The invention provides a dosage form, comprising a melt-processed mixture of (a) a pharmaceutically effective amount of imatinib or a salt thereof, (b) at least one polymeric binder, and (c) at least one pharmaceutically acceptable non-ionic surfactant. The invention provides imatinib dosage forms with high drug loading which can be prepared in a simple and efficient manner, imatinib dosage forms from which the active principle is released in an essentially pH-independent fashion, and extended release imatinib dosage forms.
Type:
Grant
Filed:
November 8, 2007
Date of Patent:
September 23, 2014
Assignees:
Abbvie Deutschland GmbH & Co. KG, Novartis AG
Inventors:
Jörg Breitenbach, Norbert Steiger, Harald Hach, Ulrich Westedt, Martin Knobloch, Ralf Altenburger, Nicoletta Loggia, Jörg Ogorka
Abstract: The present invention relates to methods of treating subjects suffering from nephrolithiasis by administering to a subject in need of treatment thereof a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.
Abstract: An improved pharmaceutical formulation for oral administration includes a therapeutically effective quantity of an active ingredient and a stabilizer. The active ingredient is Fluvastatin, or pharmaceutically acceptable salts thereof, and the stabilizer is a mixture of Carrageenans. The stabilizer inhibits isomerization, and/or elimination, and/or oxidation and/or recrystallization of the active ingredient.
Abstract: One aspect of the present invention relates to a method of treating or preventing pathologic sequelae of acute hyperglycemia and/or increased fatty acid flux in a subject. This method involves administering an ROS inhibitor to the subject. In addition, methods of promoting neovascularization, inhibiting oxidation or excessive release of free fatty acids, and identifying compounds suitable for treatment or prevention of ROS-mediated injury are also disclosed.
Type:
Grant
Filed:
May 24, 2005
Date of Patent:
September 9, 2014
Inventors:
Geoffrey C. Gurtner, Michael A. Brownlee
Abstract: An antimicrobial composition with synergistic biocidal activity is described which comprises at least one antimicrobial polymeric biguanide and at least one antimicrobial vicinal diol, said vicinal diol comprises at least one monoalkyl glycol, monoalkyl glycerol, or monoacyl glycerol, to diminish or eliminate biofilm communities. Such synergistic interaction is effective in wound treatment, particularly for chronic wounds, burns and battlefield-induced wounds, as well as for disinfecting non-biological surfaces. The antimicrobial composition can also be prepared as viscous solutions or as gels. The antimicrobial composition may be added to a substrate and dried, such as to a catheter, or to a foam, or to a fiber wound dressing, or coated as a viscous solution or gel upon such devices, to provide controlled release antimicrobial activity.
Abstract: The present invention relates to chemical total synthesis methods of six novel protein tyrosine phosphatase-1B (PTP1B) inhibitors and application of the inhibitors in the preparation of medicaments for treating type 2 diabetes mellitus (T2DM). The PTP1B inhibitors use one or more of the six compounds represented by the structural formulae 1, 2, 3, 4, 5 and 6, as active components. The compounds can enhance the sensitivity of an insulin receptor by inhibiting the activity of PTP1B, thereby having a favorable therapeutic effect on insulin-resistant T2DM.
Type:
Grant
Filed:
July 7, 2011
Date of Patent:
August 26, 2014
Assignee:
Institute of Oceanology, Chinese Academy of Sciences
Abstract: Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof.
Abstract: This invention provides compounds capable of reducing drug resistance in a subject undergoing cancer treatment, methods using the compounds, compositions, and methods for identifying such compounds.
Abstract: Described herein is a method and a device for expediting delivery of an agent to a damaged bacterial cell. In one embodiment, the methods and devices are useful for screening candidate antibiotics. In another embodiment, the methods and devices described herein are used to determine susceptibility of bacteria to an antibiotic. The methods also provide a method for determining an appropriate antibiotic to treat an individual having a bacterial infection.
Type:
Grant
Filed:
October 28, 2011
Date of Patent:
July 22, 2014
Assignees:
Fraunhofer, USA, Inc., Trustees of Boston University
Inventors:
Alexis Sauer-Budge, Andre Sharon, Maxim Kalashnikov, Holger Wirz
Abstract: The present invention provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and bortezomib. The invention further provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and melphalan.
Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.